Mid-cap Health Care company Roivant Sciences has logged a -3.2% change today on a trading volume of 3,319,177. The average volume for the stock is 4,585,795.
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. Based in London, United Kingdom the company has 908 full time employees and a market cap of $8,509,735,424.
The company is now trading -27.26% away from its average analyst target price of $16.07 per share. The 7 analysts following the stock have set target prices ranging from $12.5 to $18.0, and on average give Roivant Sciences a rating of buy.
Over the last 52 weeks, ROIV stock has risen 2.2%, which amounts to a -22.6% difference compared to the S&P 500. The stock's 52 week high is $13.05 whereas its 52 week low is $9.69 per share. Based on Roivant Sciences's average net margin growth of 19.3% over the last 4 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2023 | 124,795 | 4,348,926 | |
| 2022 | 61,280 | -1,009,030 | -1647 |
| 2021 | 55,286 | -845,262 | -1529 |
| 2020 | 23,795 | -809,234 | -3401 |
